NCT02023996View on ClinicalTrials.gov

PET Imaging With 89Zr-DFO-Trastuzumab in Esophagogastric Cancer

NACompletedINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

December 31, 2013

Primary Completion Date

June 27, 2023

Study Completion Date

June 27, 2023

Conditions
Esophagogastric Cancer
Interventions
RADIATION

89Zr-DFO-trastuzumab

DEVICE

PET imaging

Trial Locations (1)

10065

Memorial Sloan Kettering Cancer Center, New York

All Listed Sponsors
lead

Memorial Sloan Kettering Cancer Center

OTHER

NCT02023996 - PET Imaging With 89Zr-DFO-Trastuzumab in Esophagogastric Cancer | Biotech Hunter | Biotech Hunter